NCT00292045 - Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2004

Primary Completion Date

January 9, 2006

Study Completion Date

January 9, 2006

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

NY-ESO-1 protein/CpG 7909

Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).

Trial Locations (2)

Unknown

Krankenhaus Nordwest, Frankfurt

Universitätsspital Zürich, Zurich